← All stocks

Stock news timeline · SHILPAMED

Shilpa Medicare

News timeline · Last 30 days

23 Aug 2026 – 21 Sep 2026 · Times in IST

Timeline updates
10
Bullish
5
Neutral
4
Bearish
1
Active days
4

News timeline

Showing 10 of 10 updates · Newest first

Friday, 18 Sep 20263 updates

AI sentiment: Bullish 88% confidence

Shilpa Medicare Jumps 7% on USFDA Nod, India Patent Win

Shilpa Medicare's Hyderabad unit completed USFDA inspection with one procedural observation. Shares rose 7.4% to ₹1,028.65; OERIS injection approved for India, patent valid till 2039. Source: CNBC TV 18

AI sentiment: Neutral 85% confidence

Shilpa Medicare: USFDA Inspection at Hyderabad Facility Yields One Process Remark

AI sentiment: Neutral 86% confidence

USFDA Flags 1 Issue at Shilpa Medicare's Hyderabad Unit

USFDA conducted surveillance inspection at Shilpa Medicare's Unit VII, Hyderabad, concluding with one procedural observation. Observation was not a repeat or related to data integrity; company will respond within stipulated timeline. Source: BSE

Saturday, 12 Sep 20261 update

AI sentiment: Neutral 80% confidence

Shilpa Medicare Declares ₹0.60 Dividend for FY26

Shilpa Medicare declares final dividend of INR 0.60 per share for FY 2026. Dividend announcement made during AGM held on September 11, 2026. Source: MarketScreener India

Friday, 11 Sep 20265 updates

AI sentiment: Bullish 76% confidence

Shilpa Medicare Secures US FDA Nod for Oeris Cancer Drug

Shilpa Medicare gets SEC's final approval for Oeris marketing authorization. This milestone enhances access to its supportive cancer treatment solutions. Source: Livesquawk

AI sentiment: Bullish 63% confidence

Shilpa Medicare Gets SEC Nod for OERIS; Patent Safe Till 2039

Shilpa Medicare secures SEC final approval for OERIS, an extended-release ondansetron injection. OERIS offers anti-nausea relief for 120 hours; patent protected in India till 2039. Source: ScoutQuest

AI sentiment: Bullish 86% confidence

Shilpa Medicare: Co MD Announces SEC's Final Approval for Oeris™ Marketing Authorization, A Significant Milestone in Enhancing Supportive Cancer Treatment.

AI sentiment: Bullish 56% confidence

Shilpa Medicare: Gets SEC's Final Approval To Market Oeris™ (Ondansetron Extended-Release Injection, 100 mg/ml); It's The First Extended-Release Version That Lasts For Up To 120 Hours; Launch Plans Set For India.

AI sentiment: Neutral 84% confidence

Shilpa Medicare Declares Dividend, Adopts Financials at 39th AGM

Shilpa Medicare Ltd held its 39th AGM on 11th Sept 2026 via video conferencing. Key resolutions included adoption of financials, dividend declaration, and director reappointment. Source: BSE

Thursday, 10 Sep 20261 update

AI sentiment: Bearish 43% confidence

NCLT Admits Insolvency Plea Against Shilpa Medicare Unit

NCLT admits insolvency plea against FTF Pharma, a Shilpa Medicare subsidiary. Operational debt claimed at ₹21.8 crore; CIRP initiated; parent impact unclear. Source: ScoutQuest